Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

CEREVEL THERAPEUTICS HOLDINGS, INC.

(CERE)
  Report
Delayed Nasdaq  -  04:00 2022-12-02 pm EST
29.64 USD   +4.48%
11/14Cerevel Therapeutics to Present at Upcoming Investor Conferences
AQ
11/13Cerevel Therapeutics : Binding and Signal Profiling of Full and Partial M4 Agonists
PU
11/13Cerevel Therapeutics : Efficacy of Subtype-Selective, Full vs Partial M4 Muscarinic Receptor Agonists in Modulating Amphetamine-Induced Brain Activity Assessed by Functional MRI (fMRI) in Rats
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Cerevel Therapeutics Shares Rise After Wells Fargo Initiates Coverage

09/26/2022 | 01:01pm EST


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
CEREVEL THERAPEUTICS HOLDINGS, INC. 4.48% 29.64 Delayed Quote.-8.58%
WELLS FARGO & COMPANY -1.98% 45.94 Delayed Quote.-4.25%
All news about CEREVEL THERAPEUTICS HOLDINGS, INC.
11/14Cerevel Therapeutics to Present at Upcoming Investor Conferences
AQ
11/13Cerevel Therapeutics : Binding and Signal Profiling of Full and Partial M4 Agonists
PU
11/13Cerevel Therapeutics : Efficacy of Subtype-Selective, Full vs Partial M4 Muscarinic Recept..
PU
11/13Cerevel Therapeutics : Efficacy of CV-0000042, a Novel M4 Receptor Full Agonist, and CV-00..
PU
11/11Cerevel Therapeutics to Present at Upcoming Investor Conferences
AQ
11/10Mizuho Trims Price Target on Cerevel Therapeutics Holdings to $28 From $32, Keeps Neutr..
MT
11/09HC Wainwright Trims Price Target on Cerevel Therapeutics Holdings to $48 From $50, Main..
MT
11/08Transcript : Cerevel Therapeutics Holdings, Inc., Q3 2022 Earnings Call, Nov ..
CI
11/08CEREVEL THERAPEUTICS HOLDINGS, INC. Management's Discussion and Analysis of Financial ..
AQ
11/08Cerevel Therapeutics Holdings, Inc. Reports Earnings Results for the Third Quarter and ..
CI
More news
Analyst Recommendations on CEREVEL THERAPEUTICS HOLDINGS, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -350 M - -
Net cash 2022 539 M - -
P/E ratio 2022 -12,7x
Yield 2022 -
Capitalization 4 631 M 4 631 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 285
Free-Float 82,4%
Chart CEREVEL THERAPEUTICS HOLDINGS, INC.
Duration : Period :
Cerevel Therapeutics Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CEREVEL THERAPEUTICS HOLDINGS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Last Close Price 29,64 $
Average target price 41,18 $
Spread / Average Target 38,9%
EPS Revisions
Managers and Directors
N. Anthony Coles Executive Chairman & Chief Executive Officer
Abraham N. Ceesay President
Mark Bodenrader VP-Finance, Chief Financial & Accounting Officer
John Renger Chief Scientific Officer
Raymond Sanchez Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
CEREVEL THERAPEUTICS HOLDINGS, INC.-8.58%4 631
VERTEX PHARMACEUTICALS46.34%82 493
REGENERON PHARMACEUTICALS, INC.21.36%81 852
BIONTECH SE-34.16%41 250
WUXI APPTEC CO., LTD.-34.47%32 173
GENMAB A/S24.60%30 178